Summary
BeOne Medicines Ltd. (ONC) held its Annual General Meeting on June 11, 2026, where key corporate governance and compensation matters were addressed. Notably, four directors, Michael Goller, Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders, and Qingqing Yi, did not seek re-election, and their terms concluded without disagreement. Shareholders overwhelmingly approved amendments to the Company's 2016 Share Option and Incentive Plan and the 2018 Employee Share Purchase Plan, significantly increasing the number of shares available for issuance under both. The company also received shareholder approval for its 2025 financial statements and the appropriation of accumulated losses. Significant votes of confidence were also cast for the re-election of existing directors and the election of new board members, including a new Compensation Committee member and the re-election of the Chairman of the Board. The appointment of Ernst & Young LLP as independent auditors for fiscal year 2026 was ratified.
Key Highlights
- 1Four directors did not stand for re-election; their terms expired at the Annual Meeting. This was not due to any disagreements.
- 2Shareholders approved the Fifth Amended and Restated 2016 Share Option and Incentive Plan, increasing authorized shares by 75,400,000.
- 3Shareholders approved the Sixth Amended and Restated 2018 Employee Share Purchase Plan, increasing shares available for sale by 3,250,000.
- 4The audited Swiss statutory financial statements for fiscal year 2025 and the appropriation of accumulated losses were approved by shareholders.
- 5All nominated directors, including newly elected ones, were approved for election to the Board of Directors.
- 6Mr. John V. Oyler was re-elected as Chairman of the Board of Directors.
- 7Ernst & Young LLP was ratified as the Company's independent auditor for fiscal year 2026.
- 8Shareholders approved a general mandate for the Board to issue shares (up to 20%) and repurchase shares (up to 10%).